Table 1. Baseline demographic and clinical characteristics of the 156 patients.
| Cilostazol group (N = 74) | Clopidogrel group (N = 82) | P value | |
|---|---|---|---|
| Sex, male, n (%) | 61 (82.43) | 67 (81.71) | 0.906 |
| Age, y, median (IQR) | 63 (54-70) | 68 (62-74) | 0.003＊ |
| Body mass index (kg/m2) | 25.26±2.69 | 23.96±2.58 | 0.002＊ |
| Current cigarette smoking, n (%) | 29 (39.19) | 33 (40.24) | 0.893 |
| Hypertension, n (%) | 58 (78.38) | 66 (80.49) | 0.745 |
| Diabetes mellitus, n (%) | 28 (37.84) | 27 (32.93) | 0.521 |
| History of stent placement, n (%) | 6 (8.11) | 2 (2.44) | 0.151 a |
| Hemorrhage history, n (%) | 7 (9.46) | 6 (7.32) | 0.629 |
| History of myocardial infarction, n (%) | 1 (1.35) | 3 (3.66) | 0.622 a |
| History of coronary heart disease, n (%) | 6 (8.11) | 14 (17.07) | 0.094 |
| Creatinine (μmol/L, IQR ) | 64.50 (57.00-77.00) | 67.00 (57.75-81.00) | 0.346 |
| PLT (×109/L, IQR) | 193.50 (161.50-240.25) | 198.00 (160.50-242.25) | 0.798 |
| LDL (mmol/L, IQR) | 1.86 (1.29-2.22) | 1.86 (1.49-2.44) | 0.488 |
| Admission’s mRS score (IQR) | 2 (2-3) | 2 (1-3) | 0.053 |
| Follow-up duration (month, IQR) | 13 (12-16.25) | 18 (12-29) | ＜0.01＊ |
Abbreviations: IQR, interquartile range; LDL, low-density lipoprotein; PLT, platelet count; mRS, modified Rankin Scale; Note: ＊The comparisons were statistically significant; a The comparisons were accomplished by the Fisher’s exact test.